drugset / Trial / NCT02755714

Atrovent in Exercise Induced Laryngeal Obstruction (EILO)

NCT02755714

Phase 1/2 Completed 20 enrolled Haukeland University Hospital
RandomizedCrossoverOpen-labelTreatment

Summary

Exercise Induced Laryngeal Obstruction (EILO) is a condition not uncommon in otherwise healthy young people. EILO is caused by posteromedial collapse of supraglottic structures or medialization of the vocal folds, or both, during high intensity exercise. There are currently no treatments available that is properly evidence based. However, case reports suggest a possible effect from the "asthma drug" Ipratropium Bromide (Atrovent®). The current project is an open label pilot study, aiming to test if Atrovent can influence the occurence of EILO, either postponing the onset during exercise or fully prevent the condition to occur.

Timeline

Start
2016-06-22
Primary completion
2020-10-31
Completion
2020-10-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ipratropium Small molecule 20 ug Inhaled

Indications

No indication recorded.